NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
Phase 2
Completed
- Conditions
- Epithelial MesotheliomaRecurrent Malignant MesotheliomaSarcomatous MesotheliomaStage IA Malignant MesotheliomaStage IB Malignant MesotheliomaStage II Malignant MesotheliomaStage III Malignant MesotheliomaStage IV Malignant Mesothelioma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00107432
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Cancer and Leukemia Group B, Chicago, Illinois, United States
EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer
Phase 2
Completed
- Conditions
- Primary Peritoneal Cavity CancerStage I Endometrial CarcinomaStage I Ovarian Epithelial CancerStage IA Cervical CancerStage IB Cervical CancerStage II Endometrial CarcinomaStage II Ovarian Epithelial CancerStage IIA Cervical CancerStage IIB Cervical CancerStage III Cervical Cancer
- Interventions
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00107445
- Locations
- 🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
Phase 2
Completed
- Conditions
- Adult Primary Hepatocellular CarcinomaLocalized Unresectable Adult Primary Liver CancerUnresectable Gallbladder CancerAdvanced Adult Primary Liver CancerRecurrent Adult Primary Liver CancerUnresectable Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerRecurrent Extrahepatic Bile Duct Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT00107536
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
GW572016 to Treat Recurrent Malignant Brain Tumors
Phase 2
Completed
- Conditions
- GliomaBrain TumorGlioblastoma MultiformeGBMGliosarcomaGS
- First Posted Date
- 2005-04-04
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT00107003
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Thyroid and Glucose and Energy Metabolism
- First Posted Date
- 2005-03-21
- Last Posted Date
- 2015-02-23
- Target Recruit Count
- 18
- Registration Number
- NCT00106119
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials
Not Applicable
Completed
- Conditions
- Diabetes Mellitus, Type 1
- First Posted Date
- 2005-03-14
- Last Posted Date
- 2016-06-02
- Target Recruit Count
- 120
- Registration Number
- NCT00105352
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Colorado, United States
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
Phase 1
Completed
- Conditions
- Childhood Myelodysplastic Syndromesde Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRefractory AnemiaRefractory Anemia With Excess BlastsRefractory Cytopenia With Multilineage DysplasiaSecondary Myelodysplastic SyndromesUnspecified Childhood Solid Tumor, Protocol SpecificRefractory Anemia With Ringed Sideroblasts
- Interventions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2014-06-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00104962
- Locations
- 🇺🇸
COG Phase I Consortium, Arcadia, California, United States
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
Phase 2
Completed
- Conditions
- Recurrent Thyroid CancerStage II Papillary Thyroid CancerStage IV Papillary Thyroid CancerInsular Thyroid CancerStage II Follicular Thyroid CancerStage IV Follicular Thyroid Cancer
- Interventions
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00104871
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 2
Completed
- Conditions
- Recurrent Verrucous Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Verrucous Carcinoma of the Oral CavityStage IVA Squamous Cell Carcinoma of the Lip and Oral CavityStage IVA Verrucous Carcinoma of the Oral Cavity
- Interventions
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 71
- Registration Number
- NCT00103259
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1
Terminated
- Conditions
- Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Interventions
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 74
- Registration Number
- NCT00103272
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States